Literature DB >> 21996156

Pediatric plexiform neurofibromas: impact on morbidity and mortality in neurofibromatosis type 1.

Carlos E Prada1, Fatima A Rangwala, Lisa J Martin, Anne M Lovell, Howard M Saal, Elizabeth K Schorry, Robert J Hopkin.   

Abstract

OBJECTIVE: To characterize morbidity, mortality, and surgical outcomes in pediatric patients with symptomatic plexiform neurofibromas (PNFs). STUDY
DESIGN: We conducted retrospective analysis of data from clinical records of surgical history and other neurofibromatosis type 1 (NF1)-related complications in children with PNFs seen at Cincinnati Children's Hospital Medical Center between 1997 and 2007.
RESULTS: A total of 154 children with NF1 and PNFs were identified. Children with symptomatic PNFs had increased incidence of other NF1-related tumors (P < .05). Patients with NF1 and PNFs had a higher mortality rate (5/154, 3.2%) when compared with patients without or with asymptomatic PNFs (2/366, 0.5%; P = .024). The most common morbidities leading to surgeries were neurologic, disfigurement, orthopedic, and airway complaints. Less extensive resection predicted a shorter interval to second surgery (P < .0019). The highest recurrence was seen in tumors located in the head, neck, and thorax (P < .001).
CONCLUSIONS: These findings quantify the increased risk for additional tumors and mortality associated with symptomatic PNFs. Surgical interventions were required in many cases and resulted in added morbidity in some cases. Patients with PNFs were more likely to benefit from surgery when the indications were airway compression or disfigurement. Copyright Â
© 2012 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21996156     DOI: 10.1016/j.jpeds.2011.08.051

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  47 in total

1.  Preclinical Evidence for the Use of Sunitinib Malate in the Treatment of Plexiform Neurofibromas.

Authors:  Michael J Ferguson; Steven D Rhodes; Li Jiang; Xiaohong Li; Jin Yuan; Xianlin Yang; Shaobo Zhang; Saeed T Vakili; Paul Territo; Gary Hutchins; Feng-Chun Yang; David A Ingram; D Wade Clapp; Shi Chen
Journal:  Pediatr Blood Cancer       Date:  2015-09-16       Impact factor: 3.167

Review 2.  A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor.

Authors:  Nancy Ratner; Shyra J Miller
Journal:  Nat Rev Cancer       Date:  2015-04-16       Impact factor: 60.716

3.  Preclinical assessments of the MEK inhibitor PD-0325901 in a mouse model of Neurofibromatosis type 1.

Authors:  Edwin Jousma; Tilat A Rizvi; Jianqiang Wu; David Janhofer; Eva Dombi; Richard S Dunn; Mi-Ok Kim; Andrea R Masters; David R Jones; Timothy P Cripe; Nancy Ratner
Journal:  Pediatr Blood Cancer       Date:  2015-04-22       Impact factor: 3.167

Review 4.  Current status of MEK inhibitors in the treatment of plexiform neurofibromas.

Authors:  Andrea M Gross; Eva Dombi; Brigitte C Widemann
Journal:  Childs Nerv Syst       Date:  2020-06-30       Impact factor: 1.475

5.  Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.

Authors:  Brigitte C Widemann; Dusica Babovic-Vuksanovic; Eva Dombi; Pamela L Wolters; Stewart Goldman; Staci Martin; Anne Goodwin; Wendy Goodspeed; Mark W Kieran; Bruce Cohen; Susan M Blaney; Allison King; Jeffrey Solomon; Nicholas Patronas; Frank M Balis; Elizabeth Fox; Seth M Steinberg; Roger J Packer
Journal:  Pediatr Blood Cancer       Date:  2014-04-22       Impact factor: 3.167

6.  Pediatric peripheral nerve tumors: clinical and surgical aspects.

Authors:  Fernando Guedes; Rosana Siqueira Brown; Francisco José Lourenço Torrão-Junior; Daniel A N Barbosa; Guilherme de Andrade Gagheggi Ravanini; Rogério Martin Pires Amorim
Journal:  Childs Nerv Syst       Date:  2019-07-25       Impact factor: 1.475

7.  Clinical Images: Imaging Manifestations of Orbital Neurofibromatosis Type 1.

Authors:  James M Milburn; Carlos R Gimenez; Elizabeth Dutweiler
Journal:  Ochsner J       Date:  2016

8.  Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.

Authors:  Brigitte C Widemann; Eva Dombi; Andrea Gillespie; Pamela L Wolters; Jean Belasco; Stewart Goldman; Bruce R Korf; Jeffrey Solomon; Staci Martin; Wanda Salzer; Elizabeth Fox; Nicholas Patronas; Mark W Kieran; John P Perentesis; Alyssa Reddy; John J Wright; AeRang Kim; Seth M Steinberg; Frank M Balis
Journal:  Neuro Oncol       Date:  2014-02-04       Impact factor: 12.300

9.  Neurofibroma-associated macrophages play roles in tumor growth and response to pharmacological inhibition.

Authors:  Carlos E Prada; Edwin Jousma; Tilat A Rizvi; Jianqiang Wu; R Scott Dunn; Debra A Mayes; Jose A Cancelas; Eva Dombi; Mi-Ok Kim; Brian L West; Gideon Bollag; Nancy Ratner
Journal:  Acta Neuropathol       Date:  2012-10-26       Impact factor: 17.088

10.  Sleep and pulmonary outcomes for clinical trials of airway plexiform neurofibromas in NF1.

Authors:  Scott R Plotkin; Stephanie D Davis; Kent A Robertson; Srivandana Akshintala; Julian Allen; Michael J Fisher; Jaishri O Blakeley; Brigitte C Widemann; Rosalie E Ferner; Carole L Marcus
Journal:  Neurology       Date:  2016-08-16       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.